Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) - Pipeline Review, H2 2016

Published: Jul, 2016 | Pages: 160 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) - Pipeline Review, H2 2016', provides in depth analysis on Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) targeted pipeline therapeutics. 

The report provides comprehensive information on the Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1)
- The report reviews Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) Overview 10
Therapeutics Development 11
Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) - Products under Development by Stage of Development 11
Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) - Products under Development by Therapy Area 12
Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) - Products under Development by Indication 13
Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) - Pipeline Products Glance 16
Late Stage Products 16
Early Stage Products 17
Unknown Stage Products 18
Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) - Products under Development by Companies 19
Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) - Products under Development by Universities/Institutes 28
Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) - Therapeutics Assessment 30
Assessment by Monotherapy/Combination Products 30
Assessment by Mechanism of Action 31
Assessment by Route of Administration 33
Assessment by Molecule Type 35
Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) - Companies Involved in Therapeutics Development 37
AB Science SA 37
Amgen Inc. 39
AstraZeneca Plc 40
BCI Pharma 41
Chroma Therapeutics Limited 42
CTI BioPharma Corp. 43
Deciphera Pharmaceuticals, LLC 44
Eli Lilly and Company 45
F. Hoffmann-La Roche Ltd. 46
Five Prime Therapeutics, Inc. 47
Ignyta, Inc. 48
Johnson & Johnson 49
Novartis AG 50
Pfizer Inc. 51
Plexxikon Inc. 52
SignalChem Lifesciences Corp 54
Transgene SA 55
Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) - Drug Profiles 56
AMG-820 - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
BLZ-945 - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
cediranib maleate - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
DCC-3014 - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
Drug to Antagonize CSF1R for Malignant Ascites - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
emactuzumab - Drug Profile 63
Product Description 63
Mechanism Of Action 63
R&D Progress 63
FPA-008 - Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
JNJ-28312141 - Drug Profile 67
Product Description 67
Mechanism Of Action 67
R&D Progress 67
JNJ-40346527 - Drug Profile 68
Product Description 68
Mechanism Of Action 68
R&D Progress 68
LY-3022855 - Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
masitinib - Drug Profile 70
Product Description 70
Mechanism Of Action 70
R&D Progress 70
pacritinib - Drug Profile 84
Product Description 84
Mechanism Of Action 84
R&D Progress 84
pazopanib hydrochloride - Drug Profile 95
Product Description 95
Mechanism Of Action 95
R&D Progress 95
pazopanib hydrochloride + pembrolizumab - Drug Profile 102
Product Description 102
Mechanism Of Action 102
R&D Progress 102
PD-0360324 - Drug Profile 103
Product Description 103
Mechanism Of Action 103
R&D Progress 103
pexidartinib - Drug Profile 104
Product Description 104
Mechanism Of Action 104
R&D Progress 104
PLX-73086 - Drug Profile 108
Product Description 108
Mechanism Of Action 108
R&D Progress 108
PLX-7486 - Drug Profile 109
Product Description 109
Mechanism Of Action 109
R&D Progress 109
RXDX-105 - Drug Profile 110
Product Description 110
Mechanism Of Action 110
R&D Progress 110
Small Molecule to Antagonize CSF1R for Oncology and Neuroinflammation - Drug Profile 112
Product Description 112
Mechanism Of Action 112
R&D Progress 112
Small Molecule to Antagonize FLT3 and CSF1R for AML and Inflammation - Drug Profile 113
Product Description 113
Mechanism Of Action 113
R&D Progress 113
Small Molecules to Antagonize CSF-1 Receptor for Oncology - Drug Profile 114
Product Description 114
Mechanism Of Action 114
R&D Progress 114
Small Molecules to Antagonize CSF-1R for Inflammation - Drug Profile 115
Product Description 115
Mechanism Of Action 115
R&D Progress 115
Small Molecules to Inhibit cFMS Kinase for Immunology and Oncology - Drug Profile 116
Product Description 116
Mechanism Of Action 116
R&D Progress 116
Small Molecules to Inhibit FMS for Rheumatoid Arthritis - Drug Profile 117
Product Description 117
Mechanism Of Action 117
R&D Progress 117
Small Molecules to Inhibit FMS Kinase for Central Nervous System, Gastrointestinal, Immunology and Respiratory Diseases - Drug Profile 118
Product Description 118
Mechanism Of Action 118
R&D Progress 118
sunitinib malate - Drug Profile 119
Product Description 119
Mechanism Of Action 119
R&D Progress 119
TG-3003 - Drug Profile 124
Product Description 124
Mechanism Of Action 124
R&D Progress 124
Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) - Dormant Projects 125
Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) - Discontinued Products 134
Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) - Featured News & Press Releases 140
Jul 04, 2016: Review of the conditional marketing authorization application of masitinib in amyotrophic lateral sclerosis (ALS) will follow the standard timeline of the European Medicines Agency (EMA) 140
Jun 07, 2016: Long-Term Follow Up Data For Pacritinib Presented At 2016 ASCO Annual Meeting 140
Jun 06, 2016: AB Science announces that Rapporteurs appointed by the EMA have recommended the filing of masitinib in ALS for conditional marketing authorization 144
Jun 05, 2016: Ignyta Announces Interim Data from Phase 1 Clinical Trial of Investigational Precision Medicine RXDX-105 at ASCO 2016 145
May 30, 2016: AB Science will Present Phase 3 Data in Severe Systemic Mastocytosis at the International 21St Congress of the European Hematology Association 146
May 24, 2016: Ignyta Announces RXDX-105 Phase 1 Data Presentation at the 2016 ASCO Annual Meeting 147
May 19, 2016: CTI BioPharma Announces Presentations At The American Society Of Clinical Oncology Annual Meeting 148
May 12, 2016: Five Prime Therapeutics Advances FPA008 Into Phase 2 Dose Expansion in Patients with Pigmented Villonodular Synovitis 149
May 02, 2016: AB Science has submitted to EMA the marketing authorization application for Masitinib in the Treatment of Severe Systemic Mastocytosis 149
Apr 20, 2016: Preclinical Data Presented At AACR Indicate Pacritinib Potential To Eradicate Therapy-Resistant Leukemia Stem Cells Residing In Bone Marrow Microenvironment 150
Apr 20, 2016: Deciphera's Highly-Selective Small Molecule CSF1R Immunokinase Inhibitor, DCC-3014, Demonstrates Potent Macrophage Checkpoint Inhibition as a Single Agent and In Combination with an Anti-PD1 Inhibitor 151
Apr 13, 2016: CTI BioPharma Announces Presentation on pacritinib at the American Association of Cancer Research Annual Meeting 151
Apr 11, 2016: Masitinib in Amyotrophic Lateral Sclerosis (ALS) 152
Apr 06, 2016: AB Science Will Host Live Webcast On Phase 3 Interim Analysis In ALS On 8 April 2016, 156
Apr 04, 2016: Ab Science Announces Positive Interim Results From Phase 3 Trial Of Masitinib In Amyotrophic Lateral Sclerosis 157
Appendix 159
Methodology 159
Coverage 159
Secondary Research 159
Primary Research 159
Expert Panel Validation 159
Contact Us 159
Disclaimer 160

List of Tables

Number of Products under Development for, H2 2016 11
Number of Products under Development by Therapy Area, H2 2016 12
Number of Products under Development by Indication, H2 2016 13
Comparative Analysis by Late Stage Development, H2 2016 16
Comparative Analysis by Early Stage Products, H2 2016 17
Comparative Analysis by Unknown Stage Development, H2 2016 18
Number of Products under Development by Companies, H2 2016 19
Products under Development by Companies, H2 2016 20
Products under Development by Companies, H2 2016 (Contd..1) 21
Products under Development by Companies, H2 2016 (Contd..2) 22
Products under Development by Companies, H2 2016 (Contd..3) 23
Products under Development by Companies, H2 2016 (Contd..4) 24
Products under Development by Companies, H2 2016 (Contd..5) 25
Products under Development by Companies, H2 2016 (Contd..6) 26
Products under Development by Companies, H2 2016 (Contd..7) 27
Number of Products under Investigation by Universities/Institutes, H2 2016 28
Products under Investigation by Universities/Institutes, H2 2016 29
Assessment by Monotherapy/Combination Products, H2 2016 30
Number of Products by Stage and Mechanism of Action, H2 2016 32
Number of Products by Stage and Route of Administration, H2 2016 34
Number of Products by Stage and Molecule Type, H2 2016 36
Pipeline by AB Science SA, H2 2016 37
Pipeline by Amgen Inc., H2 2016 39
Pipeline by AstraZeneca Plc, H2 2016 40
Pipeline by BCI Pharma, H2 2016 41
Pipeline by Chroma Therapeutics Limited, H2 2016 42
Pipeline by CTI BioPharma Corp., H2 2016 43
Pipeline by Deciphera Pharmaceuticals, LLC, H2 2016 44
Pipeline by Eli Lilly and Company, H2 2016 45
Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 46
Pipeline by Five Prime Therapeutics, Inc., H2 2016 47
Pipeline by Ignyta, Inc., H2 2016 48
Pipeline by Johnson & Johnson, H2 2016 49
Pipeline by Novartis AG, H2 2016 50
Pipeline by Pfizer Inc., H2 2016 51
Pipeline by Plexxikon Inc., H2 2016 52
Pipeline by SignalChem Lifesciences Corp, H2 2016 54
Pipeline by Transgene SA, H2 2016 55
Dormant Projects, H2 2016 125
Dormant Projects (Contd..1), H2 2016 126
Dormant Projects (Contd..2), H2 2016 127
Dormant Projects (Contd..3), H2 2016 128
Dormant Projects (Contd..4), H2 2016 129
Dormant Projects (Contd..5), H2 2016 130
Dormant Projects (Contd..6), H2 2016 131
Dormant Projects (Contd..7), H2 2016 132
Dormant Projects (Contd..8), H2 2016 133
Discontinued Products, H2 2016 134
Discontinued Products (Contd..1), H2 2016 135
Discontinued Products (Contd..2), H2 2016 136
Discontinued Products (Contd..3), H2 2016 137
Discontinued Products (Contd..4), H2 2016 138
Discontinued Products (Contd..5), H2 2016 139